Preclinical characterization of 55P0251, a novel compound that amplifies glucose-stimulated insulin secretion and counteracts hyperglycaemia in rodents
| Autor: | Karin, Stadlbauer, Barbara, Brunmair, Zsuzsanna, Lehner, Immanuel, Adorjan, Thomas, Scherer, Anton, Luger, Leonhardt, Bauer, Clemens, Fürnsinn |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Blood Glucose
Male Dose-Response Relationship Drug Metabolic Clearance Rate Drug Evaluation Preclinical Administration Oral Biological Availability Drugs Investigational Incretins Glucagon-Like Peptide-1 Receptor Mice Inbred C57BL Rats Sprague-Dawley Islets of Langerhans Alkaloids KATP Channels Hyperglycemia Glucose Intolerance Insulin Secretion Animals Hypoglycemic Agents Insulin Half-Life |
| Zdroj: | Diabetes, obesitymetabolism. 19(8) |
| ISSN: | 1463-1326 |
| Popis: | 55P0251 is a novel compound with blood glucose lowering activity in mice, which has been developed from a molecular backbone structure found in herbal remedies. We here report its basic pharmacological attributes and initial progress in unmasking the mode of action.Pharmacokinetic properties of 55P0251 were portrayed in several species. First efforts to elucidate the glucose lowering mechanism in rodents included numerous experimental protocols dealing with glucose tolerance, insulin secretion from isolated pancreatic islets and comparison to established drugs.A single oral dose of 55P0251 improved glucose tolerance in mice with an ED55P0251 is a novel compound that potently counteracts hyperglycaemia in rodents via amplification of glucose-stimulated insulin release. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text